Boston Financial Mangement LLC Has $4.11 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Boston Financial Mangement LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,320 shares of the company's stock after buying an additional 300 shares during the quarter. Boston Financial Mangement LLC's holdings in Eli Lilly and Company were worth $4,107,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of LLY. AMF Tjanstepension AB lifted its stake in Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company's stock valued at $293,964,000 after buying an additional 176,552 shares in the last quarter. Values Added Financial LLC lifted its position in shares of Eli Lilly and Company by 4.9% in the third quarter. Values Added Financial LLC now owns 366 shares of the company's stock worth $324,000 after purchasing an additional 17 shares in the last quarter. GAM Holding AG lifted its position in shares of Eli Lilly and Company by 55.3% in the third quarter. GAM Holding AG now owns 29,978 shares of the company's stock worth $26,559,000 after purchasing an additional 10,677 shares in the last quarter. Liberty Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 5.7% in the third quarter. Liberty Capital Management Inc. now owns 2,150 shares of the company's stock worth $1,905,000 after purchasing an additional 115 shares in the last quarter. Finally, Global X Japan Co. Ltd. lifted its position in shares of Eli Lilly and Company by 10.6% in the third quarter. Global X Japan Co. Ltd. now owns 2,614 shares of the company's stock worth $2,316,000 after purchasing an additional 251 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price objective on the stock. Finally, Barclays dropped their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $997.50.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $1.00 during midday trading on Friday, hitting $874.12. The company had a trading volume of 3,937,537 shares, compared to its average volume of 3,765,032. The business's 50 day simple moving average is $799.63 and its two-hundred day simple moving average is $846.07. The stock has a market cap of $829.82 billion, a PE ratio of 74.65, a P/E/G ratio of 1.39 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 51.24%.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.